Merdury Biopharmaceutical Corporation
Update：2026/09/15
Industries
Main Industry
Biotechnology
Main Product/Service
Merdury offers custom drug formulation and manufacturing services based on its StackDose™ platform — including formulation design, small‑scale prototyping, development of specialized tablet structures, and 3D‑printing mass‑production — and licenses its te
Founded Year
2019
Unified Business No.
82959747
Status
Active
Number of Employees
19
Total Paid-in
Capital
108,149,026 (NT$)
Location of Company
Taiwan
, New Taipei City
Exit Status
Emerging Stock Exchange(2022)
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Merdury Biopharmaceutical Corporation, founded in 2019, is a pharmaceutical company dedicated to leveraging advanced 3D powder‑printing processes to innovate drug formulation and manufacturing; through its proprietary StackDose™ platform, it aims to develop and produce next‑generation specialty dosage drugs — pushing pharmaceutical technology forward with precision release and high added‑value medicine.
